Earlier this year, PTC Therapeutics and Novartis' experimental therapy for Huntington's, mRNA splicing modifier PTC518 ...

In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation ...

Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...

A new UK startup called Dalton Tx emerged from stealth with seed financing of £4 million ($5.4 million) and a mission to ...

According to a head-to-head trial called DEVOTE, which underpins the application, the high-dose of nusinersen slowed ...

The Houston facility has been selected as one that will make orforglipron, Lilly's new oral GLP-1 agonist for weight-loss, ...

The UK’s National Cancer Plan rightly puts patients at the heart of its ambitions, with a focus on prevention, early diagnosis, and support for those living with and beyond cancer. In practice, this ...

For more information about Axtria, please visit: www.axtria.com ...

Panellists voted by 8 to 3 – with one abstention – to change the CDC recommendations to state that MMRV is not recommended ...

The knock-on effect of that now, for Scholar Rock, is a delay to approval of the Biologics License Application (BLA) for SMA ...

Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy ...

It’s a matter of public record that if HHS Secretary Robert F. Kennedy Jr had his way, he’d ban direct-to-consumer pharma ...